Apelin is the endogenous ligand for the previously orphaned G protein-coupled receptor,
APJ. This novel peptidic signalling pathway is widely represented in the heart and …

Apelin, the endogenous ligand for the G-protein-coupled APJ receptor, is emerging as a key
hormone in cardiovascular homoeostasis. It is expressed in a diverse range of tissues with …

The apelin-APJ system is a novel neurohormonal pathway, with studies to date suggesting
that it may be of pathophysiologic relevance in heart failure and may indeed be a viable …

Signaling by the peptide ligand apelin and its cognate G protein-coupled receptor APJ has a
potent inotropic effect on cardiac contractility and modulates systemic vascular resistance …

Background: Apelin, the novel endogenous ligand for the G‐protein‐coupled receptor APJ,
has shown positive inotropic, vasodilatory and diuretic properties in animal studies …

Background—Apelin is among the most potent stimulators of cardiac contractility known.
However, no physiological or pathological role for apelin–angiotensin receptor-like 1 (APJ) …

Apelin is a novel peptide that acts through the APJ receptor, sharing similarities with the
angiotensin II–angiotensin II type 1 receptor pathway. It is a peripheral vasodilator, powerful …

Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ
coupling may provide a means of enhancing myocardial function. The alterations in apelin …

Cardiac apelin has recently been suggested to contribute to the pathophysiology of heart
failure (HF) in humans. In animal experiments, its infusion acutely improved systolic as well …

Studies have shown significant cardiovascular effects of exogenous apelin administration,
including the potent activation of cardiac contraction. However, the role of the endogenous …